Bristol-Myers Squibb Company ( NYSE:BMY ) stock is about to trade ex-dividend in two days. The ex-dividend date is ...

A New York federal judge has dismissed a $6.4 billion lawsuit against Bristol Myers Squibb, agreeing with counsel for the ...

For the second time in 19 months, a federal judge in New York has dismissed a lawsuit claiming that Bristol Myers Squibb slow ...

Prime Medicine, founded by David Liu, is finding that the path of translating scientific breakthroughs to treatments is ...

This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...

Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The ...

The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S. living with ...

From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...

The new drug, Bristol Myers Squibb’s Cobenfy, targets a different area of the brain than traditional antipsychotic drugs to ...

Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...

In the “grandma gets scammed” comedy, June Squibb plays a 93-year-old who sends $10,000 in cash to con artists because she’s ...

Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...